Table 3.
Inflation adjusted and outcomes discounted cost-effectiveness analysis based on induction regimens for low and high-risk recipients.
| Strategy | Cost (C), 2013 USD value | Incremental Cost, 2013 USD value | Effect (E), years | Incremental Effect, years | C/E | ICER |
|---|---|---|---|---|---|---|
| LOW-RISK* | ||||||
| Alemtuzumab | 125,316 | 2.64 | 47.468 | |||
| r-ATG | 136,185 | 10,869 | 2.64 | 0.00 | 51,585 | |
| HIGH-RISK | ||||||
| IL2-RA | 154,088 | 2.43 | 63,410 | |||
| r-ATG | 159,894 | 5,806 | 2.48 | 0.05 | 64,473 | 116,120 |
| High-risk subcategories | ||||||
| PRA>20% | ||||||
| IL2-RA | 154,268 | 2.43 | 63,484 | |||
| r-ATG | 157,567 | 3,299 | 2.49 | 0.06 | 63,279 | 54,983 |
| KDPI> 50% | ||||||
| IL2-RA | 162,431 | 2.38 | 68,243 | |||
| r-ATG | 167,160 | 4,729 | 2.42 | 0.04 | 69,074 | 118,225 |
| CIT>24 hours | ||||||
| IL2-RA | 153,999 | 2.46 | 62,601 | |||
| Alemtuzumab | 158,686 | 4,687 | 2.56 | 0.10 | 61,986 | 46,870 |
| Age> 60 years-old | ||||||
| IL2-RA | 156,990 | 2.41 | 65,141 | |||
| r-ATG | 163,100 | 6,110 | 2.47 | 0.06 | 66,032 | 101,833 |
| African American* | ||||||
| Alemtuzumab | 152,918 | 2.51 | 60,924 | |||
| r-ATG | 161,772 | 8,854 | 2.49 | 0.02 | 64,968 | |
*
The ICER is not included. The ICER is not defined for the low risk group because the incremental health effects among alemtuzumab and r-ATG is zero (division by zero). In the African American category, alemtuzumab is marginally dominant strategy.